Momentum in the Cryptocurrency Market: A Comprehensive Analysis under Realistic Assumptions
The Review of Asset Pricing Studies · 13.10.2026
DOI: 10.1093/rapstu/raag011 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Review of Asset Pricing Studies, online erschienen am 13.10.2026. Verfasst von Chulwoo Han und 2 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Prior studies on cryptocurrency momentum overlook liquidation risk and other real-world frictions and inadequately assess its profitability. We evaluate time-series and cross-sectional momentum addressing these issues. When portfolios are marked to market daily, many cross-sectional momentum portfolios are liquidated, and those with statistically significant mean returns often earn negative profits. The mean return is insufficient for testing profitability in the cryptocurrency market, where returns are heavily skewed and fat-tailed. Evidence of time-series momentum is strong, whereas evidence of cross-sectional momentum is almost nonexistent. Investor overconfidence and the disposition effect appear to be important drivers of cryptocurrencies’ price dynamics. Received: 7 October 2025Editor: Zhiguo HeAuthors have furnished an Internet Appendix, which is available on the Oxford University Press Web site next to the link to the final published paper online.
Zitieren
APA
Han, C., Kang, B., & Ryu, J. (2026). Momentum in the Cryptocurrency Market: A Comprehensive Analysis under Realistic Assumptions. The Review of Asset Pricing Studies. https://doi.org/10.1093/rapstu/raag011
Vancouver
Han C, Kang B, Ryu J. Momentum in the Cryptocurrency Market: A Comprehensive Analysis under Realistic Assumptions. The Review of Asset Pricing Studies. 2026. doi:10.1093/rapstu/raag011
BibTeX
@article{Han2026,
author = {Han, Chulwoo and Kang, Byeongguk and Ryu, Jehyeon},
title = {Momentum in the Cryptocurrency Market: A Comprehensive Analysis under Realistic Assumptions},
journal = {The Review of Asset Pricing Studies},
year = {2026},
doi = {10.1093/rapstu/raag011}
}
EUVIMED